133891-93-7

Upstream product

• 133915-51-2 2-[(4-bromo-2-fluorophenyl)methyl]-6-fluoro-1,2,3,4-tetrahydro-1,3-dioxo-4-isoquinolinecarboxylic acid methyl ester 
• 129688-68-2 2-[(4-Bromo-2-fluorophenyl)methyl]-6-fluoro-1,3(2H,3H)-isoquinolinedione 
• 141829-04-1 4-fluoro-2-(1,3-dimethoxy-1,3-dioxopropan-2-yl)benzoic acid 
• 142371-25-3 2-(2-Chlorocarbonyl-5-fluoro-phenyl)-malonic acid dimethyl ester 
• 1152315-50-8 6-fluorohomophthalic anhydride 
• 112734-22-2 4-bromo-2-fluorobenzylamine 
• 1006-41-3 2-bromo-4-fluorobenzoic acid 
• 129688-85-3 2-<(4-bromo-2-fluorophenyl)methyl>-6-fluoro-1,2,3,4-tetrahydro-4-(methoxycarbonyl)-1,3-dioxo-4-isoquinolineacetic acid 
• 1026328-27-7 [2-(4-Bromo-2-fluoro-benzyl)-6-fluoro-1,3-dioxo-1,2,3,4-tetrahydro-isoquinolin-4-yl]-acetic acid tert-butyl ester 

Downstream Products

• 1027282-15-0 [2-(4-Bromo-2-fluoro-benzyl)-4-chloro-6-fluoro-1,3-dioxo-1,2,3,4-tetrahydro-isoquinolin-4-yl]-acetyl chloride 

Relevant academic research and scientific papers

Facile synthesis of novel spiro[azetidine-2,4'(1H)-isoquinoline-1',3',4(2'H)-triones]

A convenient general method for the synthesis of a new heterocycle, spiro[azetidine-2,4'(1'H)-isoquinoline-1',3',4(2'H)-trione] is described. The key intermediate 2 was prepared by direct halogenation of position-4 of acid 3 with thionyl chloride, and sub

N-substituted spirosuccinimide, spiropyridazine, spiroazetidine, and acetic acid aldose reductase inhibitors derived from isoquinoline-1,3- diones. 2

The isoquinoline-1,3-dione framework featured in our clinical candidate (1) and its congener was used as the template in the design of several new series of aldose reductase inhibitors (ARIs). These series included N'- substituted spirosuccinimide, spirop

SPIRO-LACTAMS AND ANALOGS THEREOF USEFUL AS ALDOSE REDUCTASE INHIBITORS

This invention relates to spiro-lactams and their pharmaceutically acceptable salts thereof, to processes for their preparation, to methods for using the compounds, and to pharmaceutical preparations thereof. The compounds have pharmaceutical properties w

ISOQUINOLINE ACETIC ACIDS AND ACETYL CARBAMATES USEFUL AS ALDOSE REDUCTASE INHIBITORS

This invention relates to isoquinoline acetic acids and acetyl carbamates and their pharmaceutically acceptable salts thereof, to processes for their preparation, to methods for using the compounds, and to pharmaceutical preparations thereof. The compounds have pharmaceutical properties which render them beneficial for thetreatment of diabetes mellitus and associated conditions